Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 3

Bioavailability Section

Comparative bioavailability of 875 mg amoxicillin tablets in healthy human volunteers

S. Baglie, P.L. Rosalen, L.M. Franco, A.P.D.B. Ruenis, R.C.C. Baglie, G.C.N. Franco, P. Silva and F.C. Groppo

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 43 p. 350 - 354

Pharmacodynamics

Plasma and salivary amoxicillin concentrations and effect against oral microorganisms

S. Baglie, A.P. Del Bortolo Ruenis, R.H. Lopes Motta, R.C. Catelli Baglie, G.C. Nobre Franco, L.M. Franco, P.L. Rosalen, P. Silva and F.C. Groppo

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 45 p. 556 - 562

Abstract

S. Baglie, A.P. Del Bortolo Ruenis, R.H. Lopes Motta, R.C. Catelli Baglie, G.C. Nobre Franco, L.M. Franco, P.L. Rosalen, P. Silva and F.C. Groppo

¹Department of Pharmaceutical Sciences, Ponta Grossa State University, Ponta Grossa, PR, ²Piracicaba Dental School, State University of Campinas, Area of Pharmacology, Anesthesiology and Therapeutics, Piracicaba, SP, ³Department of Pharmacology, Anesthesiology and Therapeutics, Sao Leopoldo Dentistry School, Campinas, SP, ⁴Faculty of Health Sciences, Methodist University of Piracicaba, UNIMEP, Piracicaba, SP, and ⁵Bioagri Laboratories Ltda, Piracicaba, SP, Brazil
Plasma and salivary amoxicillin (AMO) concentrations were quantified following a single oral dose (875 mg) of two formulations of AMO (Amoxicillin-EMS Sigma Pharma and Amoxil BD 875 mg). In addition, the effect of amoxicillin against oral microorganisms was accessed. The open, randomized, two-period crossover study was carried out in 20 volunteers. Saliva and blood samples were collected at 0, 0.5, 1, 2, 4, 8 and 12 h after drug administration, and quantified using HPLC-ESI-MS and HPLC, respectively. Streptococci counts, anaerobe counts and total microorganism counts were obtained. No differences were observed between formulations (p > 0.05) in the plasma and salivary AMO concentrations and the pharmacokinetic parameters (Cmax, tmax, AUC0–8, and AUC0–¥) also showed no statistically significant differences between formulations (p > 0.05). Microorganism counts for the two formulations at all sampling times did not differ (p > 0.05) but all microorganism counts at 60 min post-dose showed a significant decrease (p < 0.05). Amoxicillin was effective in reducing oral microorganism levels up to 12 h post-dose.Correspondence to:
Prof. F.C. Groppo, Piracicaba Dental School, State University of Campinas, Area of Pharmacology, Anesthesiology and Therapeutics,
Av. Limeira, 901, Bairro Areiao, 13414-903 Piracicaba, SP, Brazil
Email: [email protected]

Therapeutics

A PK/PD approach on the effects of clarithromycin against oral and nasal microbiota of healthy volunteers

A.P. Del Bortolo Ruenis, G.C. Nobre Franco, S. Baglie, R.H. Lopes Motta, R.P. Simões, P.L. Rosalen, L.M. Franco, R.A. Moreno, E. Abib Jr. and F.C. Groppo

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 47 p. 96 - 103

Abstract

A.P. Del Bortolo Ruenis¹, G.C. Nobre Franco², S. Baglie⁶, R.H. Lopes Motta³, R.P. Simões¹, P.L. Rosalen¹, L.M. Franco⁴, R.A. Moreno⁵, E. Abib Jr.⁵ and F.C. Groppo¹

¹Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, ²University of Taubaté (UNITAU), Taubaté, ³Department of Physiological Sciences, São Leopoldo Dentistry School, Campinas, ⁴Faculty of Health Sciences, Methodist University of Piracicaba, Piracicaba, ⁵Synchrophar Assessoria e Desenvolvimento de Projetos Clínicos, Campinas, SP, ⁶Department of Pharmaceutical Sciences, Ponta Grossa State University, Ponta Grossa, PR, Brazil
Objective: To assess the pharmacokinetics of clarithromycin (CLR) and its effects on oral and nasal microbiota in healthy volunteers in an open, randomized, two-period crossover design. Methods: A single 500 mg oral dose of CLR (Group 1: Merck; Group 2: Klaricid) was administered observing a 1-week interval between doses. Blood samples were collected from pre-dose to 24 h. Plasmatic concentrations of CLR were quantified by the LC-MS-MS method. Saliva and nasal mucosa swabs were obtained previously and after 1.33, 2, 6 and 12 h of drug administration. Pharmacokinetics and PK/PD (t > MIC, %t > MIC and AUC_0-24/MIC ratio) parameters were estimated. The microorganism counts were obtained on different culture media. Results: No statistically significant differences were observed between the two formulations (p > 0.05) regarding the pharmacokinetic parameters. Total microorganisms, staphylococci and streptococci counts did not show statistical differences (p > 0.05) between the two groups during each sampling time. Considering the microorganisms of each group, no statistically significant differences were found after drug administration, but all differed from pre-dose counts (p < 0.05). The observed t > MIC ranged from 14.45 h (± 1.69) to 1.19 h (± 2.17) considering MICs of 0.25 µg/ml and 2.0 µg/ml, respectively. There was no correlation between any t > MIC, %t > MIC or AUC_0-24 and bacterial reduction (between 0- and 12-h periods). However, the profile of reduction of microorganisms in both saliva and nasal samples were compatible with high values of t > MIC verified for both clarithromycin formulations. Conclusion: Both formulations of clarithromycin had similar pharmacokinetics and efficacy.Correspondence to:
Prof. Dr. F.C. Groppo; Piracicaba Dental School, State University of Campinas (UNICAMP), Av. Limeira 901, ZIP 13414-903, Piracicaba, SP, Brazil
Email: [email protected]

Shopping Overview

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail